Document:

EX-10.1

CORCEPT THERAPEUTICS INCORPORATED

COMMON STOCK PURCHASE AGREEMENT

This Common Stock Purchase Agreement (“Agreement”) is made as of November 14,
2006 (the “Effective Date”), by and among Corcept Therapeutics Incorporated, a Delaware
corporation (the “Company”), and each of those persons and entities, severally and not
jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto.
Such persons and entities are hereinafter collectively referred to herein as “Purchasers”
and each individually as a “Purchaser”.

AGREEMENT

In consideration of the mutual covenants contained in this Agreement, and for other good and
valuable consideration, the receipt of which is hereby acknowledged, the Company and each Purchaser
(severally and not jointly) hereby agree as follows:

SECTION 1. AUTHORIZATION OF SALE OF SHARES.

The Company has authorized the sale and issuance of 3,000,000 shares of its Common Stock, par
value $0.001 per share (the “Common Stock”), on the terms and subject to the conditions set
forth in this Agreement. The shares of Common Stock sold hereunder shall be referred to herein as
the “Shares”.

SECTION 2. AGREEMENT TO SELL AND PURCHASE THE SHARES.

2.1 Sale of Shares. At the Closing (as defined in Section 3), the Company will sell to each
Purchaser, and each Purchaser will purchase from the Company, at a purchase price of $1.00 per
Share, the number of Shares set forth next to such Purchaser’s name on the Schedule of Purchasers.

2.2 Separate Agreement. Each Purchaser shall severally, and not jointly, be liable for only
the purchase of the Shares that appear on Exhibit A hereto and that relate to such
Purchaser. The Company’s agreement with each of the Purchasers is a separate agreement, and the
sale of Shares to each of the Purchasers is a separate sale. The obligations of each Purchaser
hereunder are expressly not conditioned on the purchase by any or all of the other Purchasers of
the Shares such other Purchasers have agreed to purchase.

SECTION 3. CLOSING AND DELIVERY.

3.1 Closing. The Closing of the purchase and sale of the Shares pursuant to this Agreement
(the “Closing”) shall be held on December 15, 2006 at the offices of Heller Ehrman LLP, 275
Middlefield Road, Menlo Park, California 94025, or on such other date and place as may be agreed to
by the Company and the Purchasers. At or prior to the Closing, each Purchaser shall execute any
related agreements or other documents required to be executed hereunder, dated as of the date of
the Closing (the “Closing Date”).

3.2 Delivery of the Shares at the Closing. At the Closing, the Company shall deliver to each
Purchaser stock certificates registered in the name of such Purchaser, or in such nominee name(s)
as designated by such Purchaser, representing the number of shares of Common Stock to be purchased
by such Purchaser at the Closing as set forth in the Schedule of Purchasers against payment of the
purchase price for such shares. The name(s) in which the stock certificates are to be issued to
each Purchaser are set forth in the Investor Questionnaire and the Selling Stockholder Notice and
Questionnaire in the form attached hereto as Appendix I and II (the “Investor Questionnaire” and
the “Selling Stockholder Questionnaire”, respectively), as completed by each Purchaser, which shall
be provided to the Company no later than ten (10) business days prior to the Closing.

SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

Except as set forth on the Schedule of Exceptions delivered to the Purchasers concurrently
with the execution of this Agreement (the “Schedule of Exceptions”), the Company hereby
represents and warrants as of the date hereof to, and covenants with, the Purchasers as follows:

4.1 Organization and Standing. The Company has been duly incorporated and is validly existing
as a corporation in good standing under the laws of Delaware, has full corporate power and
authority to own or lease its properties and conduct its business as presently conducted, and is
duly qualified as a foreign corporation and in good standing in all jurisdictions in which the
character of the property owned or leased or the nature of the business transacted by it makes
qualification necessary, except where the failure to be so qualified would not have a material
adverse effect on the business, properties, financial condition or results or operations of the
Company (a “Company Material Adverse Effect”). The Company has no subsidiaries or equity
interest in any other entity.

4.2 Corporate Power; Authorization. The Company has all requisite corporate power, and has
taken all requisite corporate action, to execute and deliver this Agreement, sell and issue the
Shares and carry out and perform all of its obligations under this Agreement. This Agreement
constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
or similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as
limited by equitable principles generally, including any specific performance, and (iii) as to
those provisions of Section 8.3 relating to indemnity or contribution. The execution and delivery
of this Agreement does not, and the performance of this Agreement and the compliance with the
provisions hereof and the issuance, sale and delivery of the Shares by the Company will not
conflict with, or result in a breach or violation of the terms, conditions or provisions of, or
constitute a default under, or result in the creation or imposition of any lien pursuant to the
terms of, the Certificate of Incorporation or Bylaws of the Company or any statute, law, rule
(including federal and state securities laws and the rules and regulations of the NASDAQ Stock
Market (the “Principal Market”)) applicable to the Company or regulation or any state or
federal order, judgment or decree applicable to the Company or any indenture, mortgage, lease or
other material agreement or instrument to which the Company is a party or any of its properties is
subject.

4.3 Issuance and Delivery of the Shares. The Shares, when issued and paid for in compliance
with the provisions of this Agreement, will be validly issued, fully paid and nonassessable. The
issuance and delivery of the Shares is not subject to preemptive, co-sale, right of first refusal
or any other similar rights of the stockholders of the Company or any liens or encumbrances.
Assuming the accuracy of the representations made by each Purchaser in Section 5, the offer and
issuance by the Company of the Shares is exempt from registration under the 1933 Act..

4.4 SEC Documents; Financial Statements. The Company has filed in a timely manner all
documents that the Company was required to file with the Securities and Exchange Commission (the
“Commission”) under Sections 13, 14(a) and 15(d) the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), since becoming subject to the requirements of the Exchange
Act. As of their respective filing dates (or, if amended prior to the date of this Agreement, when
amended), all documents filed by the Company with the Commission (the “SEC Documents”)
complied in all material respects with the requirements of the Exchange Act and the rules and
regulations of the Commission promulgated thereunder. None of the SEC Documents as of their
respective dates contained any untrue statement of material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements made therein, in light of
the circumstances under which they were made, not misleading. The financial statements of the
Company included in the SEC Documents (the “Financial Statements”) comply as to form in all
material respects with applicable accounting requirements and with the published rules and
regulations of the Commission with respect thereto. The Financial Statements have been prepared in
accordance with United States generally accepted accounting principles consistently applied and
fairly present the financial position of the Company at the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of unaudited statements,
to normal, recurring adjustments).

4.5 Capitalization. All of the Company’s outstanding shares of capital stock have been duly
authorized and validly issued and are fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and were not issued in violation of or subject to any
preemptive right or other rights to subscribe for or purchase securities. The authorized capital
stock of the Company consists of 140,000,000 shares of common stock and 10,000,000 shares of
undesignated Preferred Stock, none of which are issued and outstanding as of the Effective Date.
As of the Effective Date, there are 22,731,766 shares of Common Stock issued and outstanding, of
which no shares are owned by the Company. There are no other shares of any other class or series
of capital stock of the Company issued or outstanding. The Company has no capital stock reserved
for issuance, except that, as of the Effective Date, there are 1,901,481 shares of Common Stock
reserved for issuance pursuant to options outstanding on such date pursuant to the Company’s 2000
Stock Option Plan and 2004 Equity Incentive Plan. There are no bonds, debentures, notes or other
indebtedness having general voting rights (or convertible into securities having such rights)
(“Voting Debt”) of the Company issued and outstanding.  Except as stated above, there are
no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or
commitments of any character, relating to the issued or unissued capital stock of the Company,
obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire
or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired
any capital stock or Voting Debt of, or other equity interest in, the Company or securities or
rights convertible into or exchangeable for such shares or equity interests or obligations of the
Company to grant, extend or enter into any such option, warrant, call, subscription or other right,
agreement, arrangement or commitment.  The issuance of Common Stock or other securities pursuant to
any provision of this Agreement will not give rise to any preemptive rights or rights of first
refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar
rights. Except as disclosed in the SEC Documents, there are no agreements or arrangements under
which the Company or any of its Subsidiaries is obligated to register the sale of any of their
securities under the 1933 Act. There are no securities or instruments containing anti-dilution
provisions that will be triggered by the issuance of the Shares. The Company has made available
upon request of the Purchasers, a true, correct and complete copy of the Company’s Certificate of
Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”),
and the Company’s Bylaws, as amended and as in effect on the date hereof (the “Bylaws”).

4.6 Litigation. There is no pending or, to the Company’s knowledge, threatened, action, suit
or other proceeding to which the Company is a party or to which its property or assets are subject.

4.7 Governmental Consents. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state, or local governmental
authority on the part of the Company is required in connection with the consummation of the
transactions contemplated by this Agreement except for (a) compliance with the securities and blue
sky laws in the states and other jurisdictions in which shares of Common Stock are offered and/or
sold, which compliance will be effected in accordance with such laws, and (b) the filing of a
registration statement and all amendments thereto with the Commission as contemplated by Section
8.1 of this Agreement.

4.8 No Material Adverse Change. Since September 30, 2006, except as disclosed in the SEC
Documents, there have not been any changes in the assets, liabilities, financial condition or
operations of the Company from that reflected in the Financial Statements for the quarter ended
September 30, 2006 except changes which have not had, either individually or in the aggregate, a
Company Material Adverse Effect.

4.9 No General Solicitation. Neither the Company, nor any of its affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general
advertising (within the meaning of Regulation D promulgated under the Securities Act of 1933, as
amended (the “Securities Act”)) in connection with the offer or sale of the Shares.

4.10 No Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates,
or any Person acting on their behalf has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under circumstances that would require
registration of any of the Shares under the 1933 Act or cause this offering of the Shares to be
integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable
stockholder approval provisions, including, without limitation, under the rules and regulations of
the Principal Market.

4.11 Sarbanes-Oxley Act. To the knowledge of the executive officers of the Company, the
Company is in material compliance with the requirements of the Sarbanes-Oxley Act of 2002 that are
effective and applicable to the Company as of the date hereof, and the rules and regulations
promulgated by the SEC thereunder that are effective and applicable to the Company as of the date
hereof.

4.12 Patents and Trademarks. To the knowledge of the executive officers of the Company, the
Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, copyrights, licenses and other
similar rights that are necessary or material for use in connection with their respective
businesses as described in the SEC Documents and which the failure to so have could, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect
(collectively, the “Intellectual Property Rights”).  Except as set forth in the SEC Documents,
neither the Company nor any Subsidiary has received a written notice that the Intellectual Property
Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person. 
Except as set forth in the SEC Documents, to the knowledge of the executive officers of the
Company, all such Intellectual Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property Rights.

4.13 Listing and Maintenance Requirements. Except as specified in the SEC Documents, the
Company has not, in the two years preceding the date hereof, received notice from the Principal
Market to the effect that the Company is not in compliance with the listing or maintenance
requirements thereof.  Except as disclosed in the SEC Documents, the Company is in compliance with
the listing and maintenance requirements for continued listing of the Common Stock. The issuance
and sale of the Shares under this Agreement does not contravene the rules and regulations of the
Principal Market and no approval of the shareholders of the Company thereunder is required for the
Company to issue and deliver to the Purchasers the Shares.

4.14  Disclosure. The Company understands and confirms that the Purchasers will rely on the
foregoing representations and covenants in effecting transactions in securities of the Company.  To
the knowledge of the executive officers of the Company, all due diligence materials regarding the
Company, its business and the transactions contemplated hereby, furnished by or on behalf of the
Company to the Purchasers upon their request are, when taken together with the SEC Documents, true
and correct in all material respects and do not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in light of
the circumstances under which they were made, not misleading.

SECTION 5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS.

5.1 Each Purchaser, severally and not jointly, represents and warrants to and covenants with
the Company that:

(a) Purchaser, taking into account the personnel and resources it can practically bring to
bear on the purchase of the Shares contemplated hereby, is knowledgeable, sophisticated and
experienced in making, and is qualified to make, decisions with respect to investments in shares
presenting an investment decision like that involved in the purchase of the Shares, including
investments in securities issued by the Company, and has requested, received, reviewed and
considered all information Purchaser deems relevant (including the SEC Documents) in making an
informed decision to purchase the Shares.

(b) Purchaser is acquiring the Shares pursuant to this Agreement in the ordinary course of its
business and for its own account for investment only and with no present intention of distributing
any of such Shares or any arrangement or understanding with any other persons regarding the
distribution of such Shares, except in compliance with Section 5.1(c).

(c) Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise
dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of
the securities purchased hereunder except in compliance with the Securities Act, applicable blue
sky laws, and the rules and regulations promulgated thereunder.

(d) Purchaser has, in connection with its decision to purchase the Shares, relied with respect
to the Company and its affairs solely upon the SEC Documents and the representations and warranties
of the Company contained herein.

(e) Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D
promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule
144A promulgated under the Securities Act.

(f) Purchaser has full right, power, authority and capacity to enter into this Agreement and
to consummate the transactions contemplated hereby and has taken all necessary action to authorize
the execution, delivery and performance of this Agreement. Upon the execution and delivery of this
Agreement by Purchaser, this Agreement shall constitute a valid and binding obligation of
Purchaser, enforceable in accordance with its terms, except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the
enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally,
including any specific performance, and (iii) as to those provisions of Section 8.3 relating to
indemnity or contribution.

(g) Purchaser is not a broker or dealer registered pursuant to Section 15 of the Securities
Exchange Act of 1934 (a “registered broker-dealer”) and is not affiliated with a registered broker
dealer. Purchaser is not party to any agreement for distribution of the Shares.

(h) The Purchaser shall have completed or caused to be completed and delivered to the Company
at no later than 10 business days prior to the Closing Date, the Investor Questionnaire and the
Selling Stockholder Questionnaire for use in preparation of the Registration Statement, and the
answers to the Questionnaires are true and correct in all material respects as of the date of this
Agreement and will be true and correct as of the Closing Date and the effective date of the
Registration Statement; provided that the Purchasers shall be entitled to update such information
by providing notice thereof to the Company before the effective date of such Registration
Statement.

5.2 Purchaser represents, warrants and covenants to the Company that Purchaser has not, either
directly or indirectly through an affiliate, agent or representative of the Company, engaged in any
transaction in the Securities of the Company subsequent to October 15, 2006. Purchaser represents
and warrants to and covenants with the Company that Purchaser has not engaged and will not engage
in any short sales of the Company’s Common Stock prior to the effectiveness of the Registration
Statement (either directly or indirectly through an affiliate, agent or representative).

5.3 Purchaser understands that nothing in this Agreement or any other materials presented to
Purchaser in connection with the purchase and sale of the Shares constitutes legal, tax or
investment advice. Purchaser has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares.

5.4 Legends. It is understood that the Shares may bear one or more legends in substantially
the following form and substance:

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW, AND MAY NOT BE OFFERED, SOLD,
TRANSFERRED, ENCUMBERED OR OTHERWISE DISPOSED OF EXCEPT UPON SATISFACTION OF CERTAIN
CONDITIONS, WHICH ARE SET FORTH IN THAT CERTAIN “COMMON STOCK PURCHASE AGREEMENT”
DATED NOVEMBER      , 2006, WHICH ALSO CONTAINS VARIOUS OTHER PROVISIONS AFFECTING
THESE SECURITIES, BINDING UPON TRANSFEREES HEREOF. INFORMATION CONCERNING THESE
RESTRICTIONS AND PROVISIONS MAY BE OBTAINED FROM THE CORPORATION OR ITS LEGAL
COUNSEL.”

In addition stock certificates representing the Shares may contain:

(a) Any legend required by the laws of the State of California, including any legend required
by the California Department of Corporations.

(b) Any legend required by the blue sky laws of any other state to the extent such laws are
applicable to the sale of the Shares hereunder.

5.5 Restricted Securities. Purchaser understands that the Shares are characterized as
“restricted securities” under the federal securities laws inasmuch as they are being acquired from
the Company in a transaction not involving a public offering and that under such laws and
applicable regulations such Shares may be resold without registration under the Securities Act only
in certain limited circumstances. In this connection, such Purchaser represents that it is
familiar with Commission Rule 144, as presently in effect, and understands the resale limitations
imposed thereby and by the Securities Act.

SECTION 6. CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING.

The Company’s obligation to complete the sale and issuance of the Shares and deliver shares of
Common Stock to each Purchaser, individually, as set forth in the Schedule of Purchasers shall be
subject to the following conditions to the extent not waived by the Company:

6.1 Receipt of Payment. The Company shall have received payment, by wire transfer of
immediately available funds, in the full amount of the purchase price for the number of Shares
being purchased by such Purchaser at the Closing as set forth in the Schedule of Purchasers.

6.2 Representations and Warranties. The representations and warranties made by such Purchaser
in Section 5 hereof shall be true and correct in all material respects when made and shall be true
and correct in all material respects on the Closing Date.

SECTION 7. CONDITIONS TO PURCHASERS’ OBLIGATIONS AT THE CLOSING.

Each Purchaser’s obligation to accept delivery of the Shares and to pay for the Shares shall
be subject to the following conditions to the extent not waived by such Purchaser:

7.1 Representations and Warranties Correct. The representations and warranties made by the
Company in Section 4 hereof shall be true and correct in all material respects when made and any
failure of such representations and warranties to be true and correct in all material respects
after the date hereof shall not have resulted in a Company Material Adverse Effect as of the
Closing Date.

7.2 Compliance Certificate. Each Purchaser shall have received a certificate signed by an
officer of the Company certifying to the fulfillment of the conditions set forth in Section 7.

SECTION 8. REGISTRATION OF THE SHARES; COMPLIANCE WITH THE SECURITIES ACT.

8.1 Registration Procedures and Expenses. The Company is obligated to do the following:

(a) The Company shall use its commercially reasonable efforts to prepare and file with the
Commission, not later than the second business day after the date on which the Company files its
annual report on Form 10-K for its fiscal year ending December 31, 2006 with the SEC, a
registration statement on Form S-3 (or such other registration form that the Company may then be
eligible to use) in order to register with the Commission the resale by the Purchasers, from time
to time, of the Shares through Nasdaq or the facilities of any national securities exchange on
which the Company’s Common Stock is then traded, or in privately-negotiated transactions (a
“Registration Statement”). The Company shall use its commercially reasonable efforts to
cause such Registration Statement to be declared effective as soon thereafter as reasonably
practicable.

(b) If such a Registration Statement has been filed, the Company shall use its commercially
reasonable efforts to prepare and file with the Commission (i) such amendments and supplements to
the Registration Statement and the prospectus used in connection therewith, (ii) such SEC reports
and (iii) such other filings required by the Commission, in each case as may be necessary to keep
the Registration Statement effective and not misleading until the earliest of (A) the second
anniversary date of the Closing Date, or (B) such time as all of the Shares held by the Purchasers
can be sold within a given three-month period pursuant to Rule 144 under the Securities Act.
Notwithstanding the foregoing, following the effectiveness of the Registration Statement, the
Company may, at any time, suspend the effectiveness of the Registration Statement for up to 60
days, as appropriate (a “Suspension Period”), by giving notice to the Purchasers, if the
Company shall have determined that the Company may be required to disclose any material corporate
development. Notwithstanding the foregoing, the Company may not suspend the effectiveness of the
Registration Statement more than twice during any twelve-month period. Each Purchaser agrees that,
upon receipt of any notice from the Company of a Suspension Period, such Purchaser will not sell
any Shares pursuant to the Registration Statement until (i) such Purchaser is advised in writing by
the Company that the use of the applicable prospectus may be resumed, (ii) such Purchaser has
received copies of any additional or supplemental or amended prospectus, if applicable, and (iii)
such Purchaser has received copies of any additional or supplemental filings which are incorporated
or deemed to be incorporated by reference in such prospectus.

(c) In order to facilitate the public sale or other disposition of all or any of the Shares by
each Purchaser, the Company shall furnish to each Purchaser with respect to the Shares registered
under the Registration Statement such number of copies of prospectuses, prospectus supplements and
preliminary prospectuses as such Purchaser reasonably requests in conformity with the requirements
of the Securities Act.

(d) The Company shall file any documents required of the Company for normal blue sky clearance
in states specified in writing by each Purchaser; provided, however, that the Company shall not be
required to qualify to do business or consent to service of process in any jurisdiction in which it
is not now so qualified or has not so consented.

(e) Other than fees and expenses, if any, of counsel or other advisers to the Purchasers,
which fees and expenses shall be borne by the Purchasers, the Company shall bear all expenses
(exclusive of any brokerage fees, underwriting discounts and commissions) in connection with the
procedures in paragraphs (a) through (d) of this Section 8.1.

(f) With a view to making available to the Purchasers the benefits of Rule 144 promulgated
under the Securities Act (“Rule 144”) and any other rule or regulation of the Commission
that may at any time permit a Purchaser to sell Shares to the public without registration or
pursuant to registration, the Company covenants and agrees to use its commercially reasonable
efforts to: (i) make and keep public information available, as those terms are understood and
defined in Rule 144, until the earlier of (A) the second anniversary of the Closing Date or (B)
such date as all of the Shares shall have been resold; (ii) file with the Commission in a timely
manner all reports and other documents required of the Company under the Exchange Act; and (iii)
furnish to any Purchaser upon request, as long as the Purchaser owns any Shares, (A) a written
statement by the Company that it has complied with the reporting requirements of the Exchange Act,
(B) a copy of the most recent annual or quarterly report of the Company, and (C) such other
information as may be reasonably requested in order to avail any Purchaser of any rule or
regulation of the Commission that permits the selling of any such Shares without registration under
the Securities Act.

8.2 Transfer of Shares After Registration. Each Purchaser agrees that such Purchaser will not
effect any disposition of the Shares that would constitute a sale within the meaning of the
Securities Act, except:

(a) pursuant to the Registration Statement, in which case such Purchaser shall submit the
certificates evidencing the Shares to the Company’s transfer agent, accompanied by a separate
certificate executed by such Purchaser or by an officer of, or other authorized person designated
by, such Purchaser, to the effect that (A) the Shares have been sold in accordance with the
Registration Statement and (B) the requirement of delivering a current prospectus has been
satisfied; or

(b) in a transaction exempt from registration under the Securities Act, in which case such
Purchaser shall, prior to effecting such disposition, submit to the Company an opinion of counsel
in form and substance reasonably satisfactory to the Company to the effect that the proposed
transaction is in compliance with the Securities Act.

8.3 Indemnification. As used in this Section 8.3 the following terms shall have the following
respective meanings:

(a) “Selling Stockholder” shall mean a Purchaser of Shares under this Agreement and
any transferee of such a Purchaser who is entitled to resell Shares pursuant to the Registration
Statement;

(b) “Registration Statement” shall include any final prospectus, exhibit, supplement
or amendment included in or relating to the Registration Statement referred to in Section 8.1; and

(c) “Untrue Statement” shall include any untrue statement or alleged untrue statement,
or any omission or alleged omission to state in the Registration Statement a material fact required
to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

The Company agrees to indemnify and hold harmless each Selling Stockholder from and against
any losses, claims, damages or liabilities to which such Selling Stockholder may become subject
(under the Securities Act or otherwise) insofar as such losses, claims, damages or liabilities (or
actions or proceedings in respect thereof) arise out of, or are based upon, any Untrue Statement on
or after the effective date of the Registration Statement, or on or after the date of any
prospectus or prospectus supplement or the date of any sale by Purchaser thereunder, or arise out
of any failure by the Company to fulfill any undertaking included in the Registration Statement and
the Company will reimburse such Selling Stockholder for any reasonable legal or other expenses
reasonably incurred in investigating, defending or preparing to defend any such action, proceeding
or claim; provided, however, that the Company shall not be liable to such Selling Stockholder in
any such case to the extent that such loss, claim, damage or liability arises out of, or is based
upon, an Untrue Statement made in such Registration Statement in reliance upon and in conformity
with information furnished to the Company by or on behalf of such Selling Stockholder specifically
for use in preparation of the Registration Statement, or the failure of such Selling Stockholder to
comply with the covenants and agreements contained in Section 8.1 or 8.2 hereof respecting sale of
the Shares or any statement or omission in any Prospectus that is corrected in any subsequent
prospectus that was delivered to the Selling Stockholder prior to the pertinent sale or sales by
the Selling Stockholder.

Each Purchaser, severally and not jointly, agrees to indemnify and hold harmless the Company
(and each person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act, each officer of the Company who signs the Registration Statement and each director
of the Company) from and against any losses, claims, damages or liabilities to which the Company
(or any such officer, director or controlling person) may become subject (under the Securities Act
or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in
respect thereof) arise out of, or are based upon, any failure to comply with the covenants and
agreements contained in Section 8.1 or 8.2 hereof respecting sale of the Shares, or any Untrue
Statement contained in the Registration Statement on or after the effective date thereof, or in any
prospectus supplement as of its issue date or date of any sale by Purchaser thereunder, if such
Untrue Statement was made in reliance upon and in conformity with information furnished by or on
behalf of such Purchaser specifically for use in preparation of the Registration Statement, and
such Purchaser will reimburse the Company (or such officer, director or controlling person), as the
case may be, for any legal or other expenses reasonably incurred in investigating, defending or
preparing to defend any such action, proceeding or claim.

Promptly after receipt by any indemnified person of a notice of a claim or the beginning of
any action in respect of which indemnity is to be sought against an indemnifying person pursuant to
this Section 8.3, such indemnified person shall notify the indemnifying person in writing of such
claim or of the commencement of such action, and, subject to the provisions hereinafter stated, in
case any such action shall be brought against an indemnified person and such indemnifying person
shall have been notified thereof, such indemnifying person shall be entitled to participate
therein, and, to the extent it shall wish, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified person. After notice from the indemnifying person to such
indemnified person of its election to assume the defense thereof, such indemnifying person shall
not be liable to such indemnified person for any legal expenses subsequently incurred by such
indemnified person in connection with the defense thereof; provided, however, that if there exists
or shall exist a conflict of interest that would make it inappropriate, in the opinion of counsel
to the indemnified person, for the same counsel to represent both the indemnified person and such
indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled
to retain its own counsel at the expense of such indemnifying person; provided, however, that no
indemnifying person shall be responsible for the fees and expenses of more than one separate
counsel for all indemnified parties.

8.4 Termination of Conditions and Obligations. The conditions precedent imposed by Section 5
or this Section 8 upon the transferability of the Shares shall cease and terminate as to any
particular number of the Shares when such Shares shall have been sold or otherwise disposed of in
accordance with the intended method of disposition set forth in the Registration Statement covering
such Shares or at such time as an opinion of counsel satisfactory to the Company shall have been
rendered to the effect that such conditions are not necessary in order to comply with the
Securities Act.

8.5 Information Available. So long as the Registration Statement is effective covering the
resale of Shares owned by the Purchasers, the Company will furnish to the Purchasers, upon the
reasonable request of any Purchaser, an adequate number of copies of the prospectuses and
supplements to supply to any other party requiring such prospectuses.

8.6 Plan of Distribution. Each Purchaser agrees to distribute the Shares in compliance with
the plan of distribution set forth in the Registration Statement.

SECTION 9. BROKER’S FEE.

The Company and each Purchaser (severally and not jointly) hereby represent that there are no
brokers or finders entitled to compensation in connection with the sale of the Shares, and shall
indemnify each other for any such fees for which they are responsible.

SECTION 10. NOTICES.

All notices, requests, consents and other communications hereunder shall be in writing, shall
be sent by confirmed facsimile or mailed by first-class registered or certified airmail, or
nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so
sent in the case of facsimile transmission, or when so received in the case of mail or courier, and
addressed as follows:

(a) if to the Company, to:

Corcept Therapeutics Incorporated

149 Commonwealth Drive

Menlo Park, California 94025

Attention: Chief Executive Officer

Facsimile: (650) 327-3218

with a copy so mailed to:

Heller Ehrman LLP

275 Middlefield Road

Menlo Park, California 94025

Attention: Sarah A. O’Dowd

Facsimile: (650) 324-0638

or to such other person at such other place as the Company shall designate to the Purchasers
in writing; and

(b) if to the Purchasers, at the address as set forth at the end of this Agreement, or at such
other address or addresses as may have been furnished to the Company in writing.

SECTION 11. MISCELLANEOUS.

11.1 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed,
waived, discharged, terminated, modified or amended except upon the written consent of the Company
and holders of at least a majority of the Shares (including, for such purpose, only those Shares
not resold under the Registration Statement).

11.2 Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement.

11.3 Severability. In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby.

11.4 Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of California as applied to contracts entered into and performed entirely in
California by California residents, without regard to conflicts of law principles.

11.5 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one
instrument, and shall become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties.

11.6 Successors and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
executors and administrators of the parties hereto.

11.7 Entire Agreement. This Agreement and other documents delivered pursuant hereto,
including the exhibit and the Schedule of Exceptions, constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof and thereof.

11.8 Payment of Fees and Expenses. Each of the Company and the Purchasers shall bear its own
expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions
contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the
terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees,
costs and necessary disbursements in addition to any other relief to which such party may be
entitled.

[signature pages follow]

1

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written.

CORCEPT THERAPEUTICS INCORPORATED

By: /s/ Joseph K. Belanoff, M.D.

Name: Joseph K. Belanoff, M.D.

Title: Chief Executive Officer

2

PURCHASER:

	 
	PAPERBOY VENTURES LLC

	By: /s/ Anthony C. Garland

	 

	Name: Anthony C. Garland

	 

	Title: Chief Financial Officer

	 

	Address: 1875 K Street NW, Suite 700
Washington, DC 20006

3

	 	 	 	 	 
	JAMES N. WILSON AND PAMELA D. WILSON, TRUSTEES	 	 
	OF THE JAMES N. WILSON AND PAMELA D. WILSON	 	 
	TRUST, U/D/T 9/28/83	 	JUDITH E. COOK AND JOSEPH C. COOK, JR. JTWROS
	 
	 	By:      /s/ Judith E. Cook

	By: /s/ James N. Wilson
	 	 	—	 
	—
	 	Judith E. Cook

	Name: James N. Wilson
	 	 	 	 
	Title: Trustee
	 	By:      /s/ Joseph C. Cook, Jr.

	 
	 	Joseph C. Cook, Jr.

	Address: c/o Corcept Therapeutics Incorporated
	 	Address:  c/o Corcept Therapeutics Incorporated

	149 Commonwealth Drive
	 	149 Commonwealth Drive
	Menlo Park, CA 94025
	 	Menlo Park, CA  94025

	 
	 	THE JUDITH E. AND JOSEPH C. COOK, JR.
	FAIRVIEW MANAGEMENT, CO. L.P.,
	 	FOUNDATION, INC.
	A Texas Limited Partnership
	 	An Indiana Not-for-Profit Corporation
	By: /s/ Joseph C. Cook, Jr.
	 	By:       /s/ Joseph C. Cook, Jr.

	 
	 	 	 	 
	Name: Joseph C. Cook, Jr.
	 	Name:  Joseph C. Cook, Jr.

	Title: General Partner
	 	Title:    President

	Address: c/o Corcept Therapeutics Incorporated
	 	Address:  c/o Corcept Therapeutics Incorporated

	149 Commonwealth Drive
	 	149 Commonwealth Drive
	Menlo Park, CA 94025
	 	Menlo Park, CA  94025

	THE DAVID L. MAHONEY AND WINNIFRED C. ELLIS
1998 FAMILY TRUST
	 	 	 	 
	By: /s/ David L. Mahoney
	 	 	 	 
	 
	 	 	 	 
	Name: David L. Mahoney
	 	 	 	 
	Title: Trustee
	 	 	 	 
	Address: c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	 	 

4

PURCHASER:

	 	 	 	 	 
	SUTTER HILL VENTURES,	 	 
	A CALIFORNIA LIMITED PARTNERSHIP	 	 
	By: /s/ G. Leonard Baker, Jr. *	 	TALLACK PARTNERS, L.P.
	—
	 	By: /s/ James C. Gaither *

	Name: G. Leonard Baker, Jr.
	 	 	—	 
	Managing Director of the General Partner
	 	James C. Gaither, General Partner

	 
	 	JEFFREY W. BIRD AND CHRISTINA R.
	 
	 	BIRD AS
	G. LEONARD BAKER, JR. AND MARY ANNE
	 	TRUSTEES OF JEFFREY W. AND
	BAKER, CO-TRUSTEES OF
	 	CHRISTINA R. BIRD TRUST AGREEMENT
	THE BAKER REVOCABLE TRUST U/A/D 2/3/03
	 	DATED 10/31/00
	By: /s/ G. Leonard Baker, Jr. *
	 	By: /s/ Jeffrey W. Bird *

	 
	 	 	 	 
	G. Leonard Baker, Jr., Trustee
	 	Jeffrey W. Bird, Trustee

	 
	 	DAVID E. SWEET AND ROBIN T. SWEET
	 
	 	AS TRUSTEES OF THE DAVID AND ROBIN
	 
	 	SWEET
	SAUNDERS HOLDINGS, L.P.
	 	LIVING TRUST DATED 7/6/04
	By: /s/ G. Leonard Baker, Jr.*
	 	By: /s/ David E. Sweet

	 
	 	 	 	 
	G. Leonard Baker, Jr., General Partner
	 	David E. Sweet, Trustee

	 
	 	TENCH COXE AND SIMONE OTUS COXE,
	 
	 	CO-TRUSTEES OF THE
	 
	 	COXE REVOCABLE TRUST U/A/D 4/23/98
	By: /s/ Lynne B. Graw *
	 	By: /s/ Tench Coxe *

	 
	 	 	 	 
	Lynne B. Graw
	 	Tench Coxe, Trustee

	* signed by David E. Sweet
Under Power of Attorney
	 	 	 	 
	Address for Sutter Hill Ventures:
	 	 	 	 
	Attention: Robert Yin
755 Page Mill Road, A-200
Palo Alto, CA 94304
Phone (650) 493-5600
	 	 	 	 

5

	 	 	PURCHASER:

	 	 	 	 	 
	 	 	Wells Fargo Bank, N.A. FBO
	Wells Fargo Bank, N.A. FBO	 	SHV Profit Sharing Plan FBO William H.
	SHV Profit Sharing Plan FBO Diane J. Naar	 	Younger, Jr.
	By: /s/ Vicki M. Bandel
	 	By:   /s/ Vicki M. Bandel

	 
	 	 	 	 
	Name: Vicki M. Bandel
	 	Name:   Vicki M. Bandel

	Title: Asst. V.P./ & Trust Officer
	 	Title:  Asst. V.P./ & Trust Officer

	Wells Fargo Bank, N.A. FBO
	 	Wells Fargo Bank, N.A. FBO
	SHV Profit Sharing Plan FBO Robert Yin
	 	SHV Profit Sharing Plan FBO David L. Anderson
	By: /s/ Vicki M. Bandel
	 	By:   /s/ Vicki M. Bandel

	 
	 	 	 	 
	Name: Vicki M. Bandel
	 	Name:   Vicki M. Bandel

	Title: Asst. V.P./ & Trust Officer
	 	Title:  Asst. V.P./ & Trust Officer

	Address for Well Fargo Bank, N.A. Trustee:
	 	 	 	 
	Attention: Vicki Bandel
600 California Street 12th Floor
MAC A0193-120
San Francisco, CA 94108
Phone (415) 396-3739
	 	 	 	 

6

EXHIBIT A

SCHEDULE OF PURCHASERS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Aggregate Purchase
	Name and Address	 	Number of Shares	 	Price
	Paperboy Ventures LLC*
1875 K Street NW, Suite 700
Washington, DC 20006
	 		1,892,527		 	$	1,892,527	 
	James N. Wilson and Pamela D.
Wilson, Trustees of the James N.
Wilson and Pamela D. Wilson Trust,
U/D/T 9/28/83
c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	100,000	 	 	$	100,000	 
	Judith E. Cook and Joseph C. Cook,
Jr. JTWROS
c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	100,000	 	 	$	100,000	 
	Fairview Management, Co. L.P.,
a Texas Limited Partnership
c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	100,000	 	 	$	100,000	 
	The Judith E. and Joseph C. Cook,
Jr. Foundation, Inc.
an Indiana not-for-profit corporation
c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	100,000	 	 	$	100,000	 
	The David L. Mahoney and Winnefred
C. Ellis 1998 Family Trust
c/o Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
	 	 	200,000	 	 	$	200,000	 
	Sutter Hill Ventures, A California
Limited Partnership**
	 	 	379,391	 	 	$	379,391	 

7

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Aggregate Purchase
	Name and Address	 	Number of Shares	 	Price
	G. Leonard Baker, Jr. and Mary Anne Baker,
Co-Trustees of The Baker Revocable Trust
U/A/D 2/3/03**
	 	 	12,621	 	 	$	12,621	 
	Saunders Holdings, L.P. **
	 	 	12,621	 	 	$	12,621	 
	Tench Coxe and Simone Otus Coxe,
Co-Trustees of Coxe Revocable Trust U/A/D
4/23/98**
	 	 	41,732	 	 	$	41,732	 
	Tallack Partners, L.P.**
	 	 	5,210	 	 	$	5,210	 
	Jeffrey W. Bird and Christina R. Bird as
Trustees of Jeffrey W. and Christina R.
Bird Trust Agreement Dated 10/31/00**
	 	 	5,059	 	 	$	5,059	 
	David E. Sweet and Robin T. Sweet as
Trustees of The David and Robin Sweet
Living Trust Dated 7/6/04**
	 	 	2,630	 	 	$	2,630	 
	Lynne B. Graw**
	 	 	761	 	 	$	761	 
	Wells Fargo Bank, N.A. FBO SHV Profit
Sharing Plan FBO William H. Younger,
Jr.***
	 	 	26,102	 	 	$	26,102	 
	Wells Fargo Bank, N.A. FBO SHV Profit
Sharing Plan FBO Diane J. Naar***
	 	 	381	 	 	$	381	 
	Wells Fargo Bank, N.A. FBO SHV Profit
Sharing Plan FBO Robert Yin***
	 	 	477	 	 	$	477	 
	Wells Fargo Bank, N.A. FBO SHV Profit
Sharing Plan FBO David L. Anderson***
	 	 	20,488	 	 	$	20,488	 
	Total:
	 	 	3,000,000	 	 	$	3,000,000	 
	*Other entities controlled directly or
indirectly by Allen Andersson may purchase
a portion of the shares allocated to
Paperboy Ventures LLC
	 	 	 	 	 	 	 	 
	**address:
	 	 	 	 	 	 	 	 
	755 Page Mill Road, A-200
Palo Alto, CA 94304
	 	 	 	 	 	 	 	 
	***address:
	 	 	 	 	 	 	 	 
	Wells Fargo Bank, N.A. FBO
Attention Vicki Bandel
600 California Street 12th Floor
MAC A0193-120San Francisco, CA 94108
	 	 	 	 	 	 	 	 

8EX-10.1

LETTER AGREEMENT

This LETTER AGREEMENT (this “Agreement”) is dated as of November 10, 2006, by and
among HERBALIFE LTD., a Cayman Islands exempted limited liability company (the “Company”),
and CCG INVESTMENTS (BVI), L.P., a British Virgin Islands limited partnership, CCG ASSOCIATES-QP,
LLC, a Delaware limited liability company, CCG ASSOCIATES-AI, LLC, a Delaware limited liability
company, CCG INVESTMENT FUND-AI, LP, a Delaware limited partnership, CCG AV, LLC — SERIES C, a
Delaware limited liability company, CCG AV, LLC — SERIES E, a Delaware limited liability company
and CCG CI, LLC, a Delaware limited liability company (collectively, the “Golden Gate
Fund”). Reference is made to that certain Registration Rights Agreement, dated as of July 31,
2002, among the Company, Whitney V, L.P., a Delaware limited partnership, and Whitney Strategic
Partners V, L.P., a Delaware limited partnership (together, “Whitney V”), Golden Gate Fund,
and the other persons and entities party thereto (the “Original Agreement”). Capitalized
terms used herein without definition shall have the meanings ascribed thereto in the Original
Agreement.

NOW, THEREFORE, the parties hereto hereby agree as follows:

Section 1. Information Rights. If at any time the Golden Gate Fund exercises its
registration rights under Section 2 or Section 3 of the Original Agreement and the Company delays,
defers or avoids such registration rights pursuant to the first proviso of Section 2(a) of the
Original Agreement, the second sentence of Section 3(b) of the Original Agreement or otherwise,
then the Company will provide the Golden Gate Fund with all reasonably requested informational
access (including access to the Company’s senior management team, including the CEO and CFO) to
assist the Golden Gate Fund in understanding the reasons for such delay, deferral or avoidance of
the Golden Gate Fund’s registration rights (all with the intent that the Golden Gate Fund be
provided informational access equivalent to that which would have been provided to the Golden Gate
Fund if it had a representative on the Company’s board of directors). The aforementioned
information rights will be subject to the condition that the Golden Gate Fund enter into a
non-disclosure agreement with the Company, which will provide that the Golden Gate Fund and its
representatives (x) shall keep all confidential and proprietary information provided to them by the
Company or its representatives pursuant to this Agreement (the “Provided Information”)
strictly confidential (subject to a customary exception for any disclosure required by applicable
law) and (y) shall not use the Provided Information for any purpose unrelated to the Golden Gate
Fund’s liquidity planning with respect to its ownership stake in the Company.

Section 2. Miscellaneous. This Agreement constitutes the entire agreement of the
parties hereto with respect to the subject matter hereof and may not be modified or amended except
in writing by the agreement of parties hereto. The terms and conditions of the Original Agreement
shall remain in full force and effect in accordance with the terms thereof.

* * * * *

1

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first
above written.

HERBALIFE LTD.

	 	 	 
	By:

	 	/s/ Brett R. Chapman     
	
 
	 	 
	
 
	 	Name: Brett R. Chapman

Title: General Counsel

	 	 	CCG INVESTMENTS (BVI), L.P.

CCG ASSOCIATES — QP, LLC

CCG ASSOCIATES — AI, LLC

CCG INVESTMENT FUND — AI, LP

CCG AV, LLC — SERIES C

CCG AV, LLC — SERIES E

CCG CI, LLC

	 	 	 
	By:

Its:

	 	Golden Gate Capital Management, L.L.C.

Authorized Representative
	By:

	 	/s/ Jesse T. Rogers     
	
 
	 	 
	Its:

	 	Jesse T. Rogers

Managing Director
	 
	 	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]